Press release
Lifeward Enters Transformative Strategic Investment and Partnership Agreement with Oramed to Create a Diversified Biomedical Innovation Company
Positions Lifeward as a MedTech platform with a clear path to cashflow positive and long-term Biotech upside potential Up to $47 million strategic investment
About this update from Oramed Pharmaceuticals Inc.
[{"type":"text","content":"Positions Lifeward as a MedTech platform with a clear path to cashflow positive and long-term Biotech upside potential Up to $47 million strategic investment from Oramed and another investor is intended to provide Lifeward cash runway to profitability and diversify its portfolio across MedTech and BioTech Lifeward acquires Oramed’s clinical-stage Protein Oral Delivery (POD™) technology adding exposure to a large, long-term Biotech market opportunity POD™ targets the $600+ billion injectable drugs market, including ORMD-0801, which has the potential to become the world’s first commercialized oral insulin medicine MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd., (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology designed to transform the lives of people with physical limitations or disabilities, announced today that it has entered into a transformative strategic partnership with Oramed Pharmaceuticals Inc. (Nasdaq: ORMP). The transaction, which has received unanimous approval from Lifeward’s board of directors and is subject to shareholder approval, includes Lifeward integrating Oramed's proprietary protein oral delivery (POD™) technology and Oramed acquiring up to a 49.99% equity ownership in Lifeward. The investment structure provides Lifeward with access to up to approximately $47 million of capital through equity, convertible notes, milestone-based funding, and warrant coverage. This capital framework is designed to support Lifeward’s path to profitability while enabling selective investment in high-value innovation. The POD™ technology, which is subject to regulatory approval, represents years of research and development in transforming injectable biological therapies into oral medications. POD™ technology was initially applied in clinical trials in diabetes, a global market exceeding $80 billion1 annually, with injectable insulin representing a substantial portion. The addressable opportunity for oral delivery can be expanded to multiple peptide and protein-based therapies across metabolic, endocrine, and inflammatory diseases, representing a global market valued at tens of billions. Under a clinical trial management agreement, Oramed will retain responsibility for managing and funding the anticipated POD™ clinical program. This structu...